Drug Profile
VCL HB01 - Fresh Tracks Therapeutics
Alternative Names: Herpes simplex DNA vaccine; HSV-2 DNA vaccine - Fresh Tracks Therapeutics; HSV-2 glycoprotein D vaccine - Fresh Tracks Therapeutics; VCL-HB01Latest Information Update: 14 Sep 2022
Price :
$50
*
At a glance
- Originator University of Washington; Vical
- Developer Fresh Tracks Therapeutics
- Class DNA vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Herpes simplex virus infections
Most Recent Events
- 07 Sep 2022 Brickell Biotech Inc is now called Fresh Tracks Therapeutics
- 31 Aug 2019 Brickell Biotech has merged with Vical to form Brickell Biotech Inc, and subsequently Brickell Biotech changed its name to Brickell Subsidiary
- 11 Jun 2018 Vical discontinued a phase II clinical trial for Herpes simplex virus infections (In adults) in USA (IM) (NCT02837575)